Amgen bond offering to help fund Horizon Therapeutics acquisition
Kameleon007         

Amgen (NASDAQ:AMGN) has started a bond offering with the proceeds being used to help fund its planned $28B acquisition of Horizon Therapeutics (HZNP).
According to the prospectus, the senior notes are due between 2025 and 2063.
The public offering price is not yet determined.
BofA, Citigroup, Goldman Sachs, and Mizuho are are acting as joint bookrunners.
In late January, the Federal Trade Commission sent a "Second Request" to the companies seeking additional information.